Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Locally Recurrent or Metastatic Soft Tissue Sarcoma Patients: a One-arm, Multi-center, Prospective Clinical Trial

NCT03815474 is registered in ClinicalTrials.gov with Liaoning Cancer Hospital & Institute as lead sponsor.

NCT NCT03815474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03815474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Locally Recurrent or Metastatic Soft Tissue Sarcoma Patients: a One-arm, Multi-center, Prospective Clinical Trial
Lead sponsor
Liaoning Cancer Hospital & Institute
Phase
Phase 2
Overall status
Unknown status
Start date
May 20, 2019
Completion date
December 31, 2020
Enrollment
47 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma, soft tissue